Pitcairn Co. Has $2.63 Million Position in Haleon plc (NYSE:HLN)

Pitcairn Co. raised its position in shares of Haleon plc (NYSE:HLN - Free Report) by 10.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 275,848 shares of the company's stock after purchasing an additional 25,661 shares during the quarter. Pitcairn Co.'s holdings in Haleon were worth $2,632,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of HLN. Wellington Management Group LLP increased its stake in Haleon by 67.5% in the 4th quarter. Wellington Management Group LLP now owns 15,328,325 shares of the company's stock valued at $146,232,000 after buying an additional 6,175,835 shares during the period. Douglas Lane & Associates LLC grew its holdings in shares of Haleon by 1.9% during the 4th quarter. Douglas Lane & Associates LLC now owns 8,624,149 shares of the company's stock valued at $82,274,000 after acquiring an additional 161,865 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of Haleon by 18.3% in the fourth quarter. JPMorgan Chase & Co. now owns 6,014,903 shares of the company's stock worth $57,382,000 after acquiring an additional 930,701 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Haleon during the fourth quarter worth $42,193,000. Finally, Bank Julius Baer & Co. Ltd Zurich purchased a new stake in shares of Haleon during the fourth quarter worth $39,628,000. Hedge funds and other institutional investors own 6.67% of the company's stock.

Haleon Stock Performance

Haleon stock traded down $0.57 on Friday, reaching $9.89. 14,127,487 shares of the stock were exchanged, compared to its average volume of 6,669,077. The stock has a market cap of $44.66 billion, a PE ratio of 29.07, a PEG ratio of 2.82 and a beta of 0.24. The firm has a fifty day moving average price of $10.03 and a two-hundred day moving average price of $9.86. Haleon plc has a twelve month low of $7.99 and a twelve month high of $10.80. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44.

Remove Ads

Haleon (NYSE:HLN - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The firm had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.38 billion. Sell-side analysts anticipate that Haleon plc will post 0.43 EPS for the current year.

Haleon Increases Dividend

The business also recently announced a -- dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be given a dividend of $0.1166 per share. The ex-dividend date is Friday, April 25th. This represents a yield of 1.6%. This is a positive change from Haleon's previous -- dividend of $0.05. Haleon's payout ratio is 58.97%.

Analyst Upgrades and Downgrades

A number of research analysts have commented on HLN shares. HSBC restated a "hold" rating on shares of Haleon in a research note on Wednesday, March 5th. Sanford C. Bernstein downgraded shares of Haleon from an "outperform" rating to a "market perform" rating in a research report on Wednesday, January 8th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Haleon in a research report on Monday, March 3rd. Hsbc Global Res downgraded Haleon from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, March 5th. Finally, Morgan Stanley downgraded Haleon from an "overweight" rating to an "equal weight" rating in a research note on Friday, January 10th. Six research analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Haleon currently has an average rating of "Hold" and an average price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.